Clinical trial
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients…
NCT00333840 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00333840 |
|---|---|
| Title | Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia |
| Official title | A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C) |
| Enrollment | 1,106 |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jun 6, 2006 |
| Last update posted | Oct 14, 2013 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, New Zealand, Norway, Spain and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: